Stay updated on Pembrolizumab Combo in Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo in Ovarian Cancer Clinical Trial page.

Latest updates to the Pembrolizumab Combo in Ovarian Cancer Clinical Trial page
- Check5 days agoChange DetectedA banner announces NIH's terminology transition from “Artificial Intelligence” to “Super Intelligence” under Executive Order 14434. The site revision advances from v3.7.1 to v3.7.2.SummaryDifference1%

- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedThe footer’s site revision label changes from v3.7.0 to v3.7.1 on the 403 error page.SummaryDifference0.2%

- Check33 days agoChange DetectedThe page now displays a 403 Forbidden error instead of showing the study record content, indicating a permissions issue on the page.SummaryDifference20%

- Check40 days agoChange DetectedThe page revision identifier was updated from v3.6.6 to v3.7.0, indicating a refresh of the page content or layout without changing the underlying study information.SummaryDifference0.1%

- Check54 days agoChange DetectedThe page footer now displays Revision: v3.6.6, replacing the previous Revision: v3.6.5, indicating a new build release.SummaryDifference0.1%

- Check68 days agoChange DetectedA citation for the Maveropepimut-S, pembrolizumab and low-dose cyclophosphamide paper was added to the Publications section, replacing the previous 'Online ahead of print' entry with the finalized Nat Commun article details (authors, title, journal, date, volume, and DOI).SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab Combo in Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Ovarian Cancer Clinical Trial page.